Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
These dynamics can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here are three stocks under $50 to avoid and some other investments you should consider instead.
Integra LifeSciences (IART)
Share Price: $15.32
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Do We Avoid IART?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 2.4% annually
- 5× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Integra LifeSciences’s stock price of $15.32 implies a valuation ratio of 5.8x forward P/E. If you’re considering IART for your portfolio, see our FREE research report to learn more.
Supernus Pharmaceuticals (SUPN)
Share Price: $48.69
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ: SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Does SUPN Give Us Pause?
- Muted 5.9% annual revenue growth over the last five years shows its demand lagged behind its healthcare peers
- Subscale operations are evident in its revenue base of $776.9 million, meaning it has fewer distribution channels than its larger rivals
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
At $48.69 per share, Supernus Pharmaceuticals trades at 3.1x forward price-to-sales. Read our free research report to see why you should think twice about including SUPN in your portfolio.
Washington Trust Bancorp (WASH)
Share Price: $31.67
Founded in 1800 and operating as Rhode Island's oldest community bank, Washington Trust Bancorp (NASDAQ: WASH) is a regional bank holding company offering commercial banking, mortgage lending, personal banking, and wealth management services.
Why Is WASH Risky?
- 4.3% annual net interest income growth over the last five years was slower than its banking peers
- Inferior net interest margin of 2.3% means it must compensate for lower profitability through increased loan originations
- Earnings per share fell by 9.6% annually over the last five years while its revenue was flat, showing each sale was less profitable
Washington Trust Bancorp is trading at $31.67 per share, or 1.1x forward P/B. To fully understand why you should be careful with WASH, check out our full research report (it’s free).
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
